Floatz logo

Opc-34712

Substance Use Disorders

University of Massachusetts, WorcesterPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Substance Use Disorders cohort.

Asset / SponsorPhaseRating
Seroquel®
Boston Medical Center
Phase 4BBB
Risperdal
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Seroquel®
Boston Medical Center
Phase 4BBB
17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL
University of Texas Southwestern Medical Center
Phase 4BB
Valproic Acid
Creighton University
Phase 4BB

View all 27 →

Same molecule, other indications

Opc-34712 is also rated in:

depressive disorderDormant
A
Indicative ·
82 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
75 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →